Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Ret Proto-Oncogene Antikörper (AA 711-756)

RET Reaktivität: Ratte WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN716651
  • Target Alle Ret Proto-Oncogene (RET) Antikörper anzeigen
    Ret Proto-Oncogene (RET)
    Bindungsspezifität
    • 27
    • 21
    • 15
    • 15
    • 14
    • 11
    • 9
    • 9
    • 8
    • 8
    • 8
    • 7
    • 6
    • 6
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 711-756
    Reaktivität
    • 162
    • 100
    • 80
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Ratte
    Wirt
    • 184
    • 22
    • 2
    • 1
    • 1
    • 1
    Kaninchen
    Klonalität
    • 180
    • 31
    Polyklonal
    Konjugat
    • 88
    • 14
    • 10
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 6
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 1
    Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert
    Applikation
    • 169
    • 81
    • 65
    • 64
    • 42
    • 27
    • 17
    • 15
    • 14
    • 9
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Kreuzreaktivität
    Ratte
    Homologie
    Human,Mouse,Dog,Cow,Chicken,Rabbit
    Aufreinigung
    Purified by Protein A.
    Immunogen
    KLH conjugated synthetic peptide derived from human Ret/HSCR1
    Isotyp
    IgG
    Top Product
    Discover our top product RET Primärantikörper
  • Applikationshinweise
    WB 1:300-5000
    ELISA 1:500-1000
    IHC-P 1:200-400
    IHC-F 1:100-500
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 μg/μL
    Buffer
    0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
    Haltbarkeit
    12 months
  • Target
    Ret Proto-Oncogene (RET)
    Andere Bezeichnung
    Ret (RET Produkte)
    Synonyme
    c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper
    Hintergrund

    Synonyms: C ret, Cadherin family member 12, CDHF 12, CDHF12, ELKS Fusion gene, HSCR 1, HSCR1, Hydroxyaryl protein kinase, MEN2A, MEN2B, MTC 1, MTC1, Multiple endocrine neoplasia and medullary thyroid carcinoma 1, Oncogene RET, Proto oncogene tyrosine protein kinase receptor ret, Proto-oncogene c-Ret, Proto-oncogene tyrosine-protein kinase receptor ret, PTC, RET, RET ELE1, Ret Proto oncogene, RET transforming sequence, RET_HUMAN, RET51.

    Background: This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed. [provided by RefSeq, Jul 2008].

    Gen-ID
    5979
    Pathways
    RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Sie sind hier:
Kundenservice